Seungkyung Kang

Seungkyung Kang

Auto-generated profile, based on publicly available information

Seungkyung Kang

Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2022 in Gastric Cancer
Verified
Journal Article
Open access
PDF file
SKSeungkyung Kang
Seungkyung Kang
MPMiree Park
Miree Park
JCJung Yeon Cho
Jung Yeon Cho
SASu Jin Ahn
Su Jin Ahn
CYChanghwan Yoon
Changhwan Yoon
SCSoo-Jeong Cho
Soo-Jeong Cho
Background Diffuse-type gastric cancer (DGC), for which Helicobacter pylori infection is a causal factor, is associated with poor prognosis among young women, possibly due to female hormones such as estrogen. We aimed to identify the carcinogenesis induced by estrogen and H. pylori in DGC. Methods We screened and selected estrogen receptor alpha (ERα)-positive (MKN45) and ERα-negative (SNU5) DGC cell lines. H. pylori strain 60190 and its isogenic mutant strain lacking cytotoxin-associated gene A (60190ΔCagA) were used to infect MKN45 cells. And the cytotoxin-related gene A (CagA) cDNA which was cloned into pSP65-SR-HA (cagA-pSP65SRa) vector was used to transfect MKN45 cells. Tumor samples were used for DGC organoid culture. Results In MKN45 cells, we found that estradiol promotes epithelial–mesenchymal transition (EMT) and stemness phenotypes via HOTAIR expression. These effects were further enhanced by the addition of CagA secreted by H. pylori but were reversed by co-treatment with fulvestrant (ICI 182,780), a selective ER degrader. We also validated the effect of estrogen on DGC organoids. ERα expression was associated with tumor invasion and HOTAIR expression in DGC patients with overt H. pylori infection. Conclusions These findings may explain the rapid DGC progression in young women with physiologically high levels of estrogen and suggest that fulvestrant with ovarian function suppression could serve as a tumor-suppressive agent in premenopausal patients with DGC.

1 January 2021 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
ENEnerelt Natsagdorj
Enerelt Natsagdorj
SKSang Gyun Kim
Sang Gyun Kim
JCJinju Choi
Jinju Choi
SKSeungkyung Kang
Seungkyung Kang
BKBokyung Kim
Bokyung Kim
SCSoo-Jeong Cho
Soo-Jeong Cho
Natsagdorj E, et al. J Gastric Cancer. 2021 Sep;21(3):258-267. https://doi.org/10.5230/jgc.2021.21.e25

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
BKBokyung Kim
Bokyung Kim
JJJin-hyung Jung
Jin-hyung Jung
KHKyungdo Han
Kyungdo Han
SKSeungkyung Kang
Seungkyung Kang
ELEunwoo Lee
Eunwoo Lee
SCSoo-Jeong Cho
Soo-Jeong Cho
Kim B, et al. J Korean Med Sci. 2023 Mar;38(13):e99. https://doi.org/10.3346/jkms.2023.38.e99

10 September 2021 in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Verified
Journal Article
Open access
PDF file
SKSeungkyung Kang
Seungkyung Kang
SCSoo-Jeong Cho
Soo-Jeong Cho
Concerns have been raised regarding the long-term use of proton pump inhibitors (PPIs) as an important risk factor for gastric cancer in clinical practice. PPIs can cause hypergastrinemia at clinical doses, and hypergastrinemia has been reported to induce malignant neoplasms in the stomach in previous animal studies. In humans, the proliferation of enterochromaffin-like (ECL) cells induced by hypergastrinemia is suspected as a potential mechanism of gastric cancer. Meanwhile, persistent Helicobacter pylori (H. pylori) infection causes gastric atrophic change, which itself is a major cause of gastric cancer, and it can further increase the risk of gastric cancer by strengthening corpus atrophy through interaction with PPIs. Recent epidemiologic studies have reported an important link between long-term PPI intake and gastric cancer risk even after successful eradication of H. pylori. However, due to the methodological limitations of observational clinical studies, the causal relationship is still not clear, and a recent big data-based study reported that long-term PPI use was not related to gastric cancer incidence. Taken together, despite the potential detrimental effects of PPIs, it is currently difficult to draw a definite conclusion about its association with gastric cancer. To minimize the possibility of gastric cancer in H. pylori-infected patients or precancerous lesions in long-term PPI users, long-term PPI administration should be limited to the minimum effective dose, and antibacterial treatment for H. pylori should be considered.